What matters here is not just the weight-loss rebound itself, but what the study can and cannot tell us about long-term health behaviour. The evidence pooled randomized and observational data, which is useful for spotting patterns after GLP-1 use, yet it cannot fully separate medication effects from the reasons people stop treatment, or from the wider support they did or did not receive. That makes the findings important, but not a simple forecast for every patient.
Another key point is that โreturn to baselineโ is not the same as โnothing was gained.โ Short-term weight reduction can still improve blood pressure, glucose control and confidence around eating and activity. The uncertainty is how durable those gains are once the medication window closes. In practice, that shifts attention away from the idea of a one-off fix and toward whether people have routines, food access and follow-up support that make healthier intake easier to sustain.
For readers interested in nutrition and behaviour change, the implication is more about maintenance than motivation. The most relevant food strategies are likely the ordinary ones that help people eat less without feeling deprived: higher satiety per calorie, predictable portions, and meals that are easier to repeat. That does not mean โdiet foodsโ alone solve the problem; adherence, affordability and how foods fit into daily life are just as important.
So the broader takeaway is cautious optimism. GLP-1 drugs may create a useful opening, but lasting benefit probably depends on what replaces the medication-driven appetite effect: stable habits, supportive environments and realistic eating patterns. The science here supports a layered approach, not a single hero intervention.
GLP-1s have been hailed as miracle drugs for their effectiveness in weight loss, but users are likely to experience rapid weight regain once they stop taking them, according to a new study by University of Oxfordโs Nuffield Department of Primary Care Health Sciences.
Weight regain is only part of the problem. Metabolic and heart health benefits associated with GLP-1s โ such as reducing high blood pressure and high cholesterol โ also reverse once patients discontinue the drugs, according to the report, which was published in peer-reviewed medical journal The BMJ.
This study underlines that GLPโ1s are not a permanent fix, which has big implications for how food and beverage companies think about innovation and positioning.
Once users come off the drugs, both weight and cardiometabolic risk factors tend to drift back toward baseline, which suggests a growing need for everyday foods that help maintain satiety and better metabolic control on fewer calories, rather than just diet branding.
For manufacturers, that points to several opportunity lanes: more portionโcontrolled, nutrientโdense formats that make it easier to stick with smaller servings.
No silver bullet
The study pooled data from 37 randomized and observational studies including 9,341 adults treated with weight loss medications, such as GLP-1 drugs, for at least eight weeks.
Researchers then tracked how much weight people regained, and how their heart and metabolic health measures changed, in the months after they stopped taking the medication, compared with people on placebo or lifestyle programs.
Learn more about GLP-1s
FoodNavigator has been tracking how GLP-1 weight-loss drugs are reshaping diets and demand across the food and beverage industry. Recent coverage looks at what rising GLP-1 adoption means for brands, retailers, and future innovation.
The GLP-1 effect: How 2026 will look for food and beverageย
The number of US adults taking GLP-1 drugs surged in 2025 and shows no sign of slowing in the new year, and while the medications are lowering obesity rates, their impact on food and beverage sales hasnโt been as bad as the industry once feared.
Could functional foods replace the need for GLP-1s?ย
As GLP-1 drugs disrupt the weight loss market, food and beverage players are racing to unlock the appetite-regulating power of functional ingredients.
GLP-1s linked to cases of illness and deathย
GLP-1 drugs have been linked to a spate of illnesses in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has suggested that several cases of acute pancreatitis (inflamed pancreas) may be linked to the drugs. Many patients have been hospitalised from this illness.ย
The study found that users gained an average 0.4 kg (just under a pound) per month after ending the treatments. Weight and risk markers associated with diabetes and heart disease returned to the pre-treatment levels in under two years, according to the report.
That weight gain came at a rate almost four times faster than that experienced after discontinuing behavioral weight management program.
โThe evidence suggests that despite their success in achieving initial weight loss, these drugs alone may not be sufficient for long-term weight control,โ according to the studyโs authors.
Consumers will need accessible, everyday tools to help preserve healthier habits, including nutrient-dense, portion-aware products, retail environments that cue healthier choices, and digital or community-based supports that can extend the benefits of lifestyle change well beyond the prescription window.
Forever drugs for weight loss?
The study noted that roughly half of GLP-1 users discontinue the drug within a year, highlighting the need for more research on how health is impacted by getting off GLP-1s.
Upon discontinuation of GLP-1s, the average user returned to their pre-treatment weight by 1.7 years, while cardiometabolic risks returned after 1.4 years.
โMonthly weight regain was also faster after weight loss drugs than after behavioral weight management programs (by 0.3 kg), independent of initial weight loss,โ the study found.
This discovery โcautions against short-term use of weight management medications.โ
More research needed
While the findings pose new considerations concerning the drugsโ long-term efficacy, even short-term weight loss can be beneficial, according to Qi Sun, associate professor of medicine at Brigham and Womenโs Hospital and associate professor in the Departments of Nutrition and Epidemiology at Harvard T.H. Chan School of Public Health.
Sun authored an essay on the study, arguing that while GLP-1 agonists โshould not be relied on as a magic cure for treating obesity,โ the drugs can have beneficial results for users.
โEven though the lifestyle intervention group eventually regained weight, the cumulative incidence of developing diabetes was lower in the lifestyle intervention group compared with placebo group,โ Sun wrote. โIn observational studies, individuals with obesity who intentionally lost โฅ4.5 kg of body weight through various strategies, ranging from dietary modifications to commercial weight loss programs, had a statistically significantly lower incidence of diabetes than their counterparts without weight loss attempts.โ
Sun added that GLP-1 users should be aware of the consequences of cessation.
Sun said that the foundation for obesity treatment should focus on healthy dietary and lifestyle practices. Medications such as GLP-1 receptor agonists, he wrote, should be โused as adjuncts.โ
โSuch practices not only help prevent excess weight gain but can also lead to numerous health benefits that go beyond weight control,โ he wrote. โEffective public health measures, such as taxation on sugary beverages, clear food labeling and subsidies for fresh fruit and vegetables, should be in place to facilitate the adherence and improvement of diet quality.โ
Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.